Synthesis and biological evaluation of 2-fluoro and 3-trifluoromethyl-phenyl-piperazinylalkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione as potential antidepressant agents

References

• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441–60
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco MD, ekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl) 2005;77:448–58
   Web of Science ®Google Scholar
• Wesołowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep 2010;62:564–77
   PubMed Web of Science ®Google Scholar
• Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009;206:345–54
   PubMed Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193–203
   PubMed Web of Science ®Google Scholar
• Naughton M, Mulrooney JB, Leonard BE. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 2000;15:397–415
   PubMed Web of Science ®Google Scholar
• Canale V, Kurczab R, Partyka A et al. Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: design, synthesis, and antidepressant properties. Part II. Eur J Med Chem 2015;92:202–11
   PubMed Web of Science ®Google Scholar
• Canale V, Guzik P, Kurczab R et al. Solid-supported synthesis, molecular modeling, and biological activity of long-chain arylpiperazine derivatives with cyclic amino acid amide fragments as 5-HT7 and 5-HT1A receptor ligands. Eur J Med Chem 2014;78:10–22
   PubMed Web of Science ®Google Scholar
• Medina RA, Vázquez-Villa H, Gómez-Tamayo JC, et al. The extracellular entrance provides selectivity to serotonin 5-HT7 receptor antagonists with antidepressant-like behavior in vivo. J Med Chem 2014;57:6879–84
   PubMed Web of Science ®Google Scholar
• Cagnotto A, Salmona M, Casagni A, et al. Ros R. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. J Med Chem 2014;57:9578–97
   PubMed Web of Science ®Google Scholar
• Kowalski P, Mitka M, Jaśkowska J, et al. New arylpiperazines with flexible versus partly constrained linker as serotonin 5-HT(1A)/5-HT(7) receptor ligands. Arch Pharm (Weinheim) 2013;346:339–48
   PubMed Web of Science ®Google Scholar
• Zajdel P, Marciniec K, Maślankiewicz A, et al. Antidepressant and antipsychotic activity of new quinoline- and isoquinolinesulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem 2013;60:42–50
   PubMed Web of Science ®Google Scholar
• Lacivita E, De Giorgio P, Patarnello D, et al. Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters. Exp Brain Res 2013;230:569–82
   PubMed Web of Science ®Google Scholar
• Zajdel P, Marciniec K, Maślankiewicz A, et al. Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation. Bioorg Med Chem 2012;20:1545–56
   PubMed Web of Science ®Google Scholar
• Lacivita E, Patarnello D, Stroth N et al. Investigations on the 1-(2-Biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin7 (5-HT7) receptor with agonist or antagonist action in vitro or ex vivo. J Med Chem 2012;55:6375–80
   PubMed Web of Science ®Google Scholar
• Volk B, Gacsályi I, Pallagi K, et al. Optimization of (arylpiperazinylbutyl)oxindoles exhibiting selective 5-HT7 receptor antagonist activity. J Med Chem 2011;54:6657–69
   PubMed Web of Science ®Google Scholar
• Hussainy RA, Verbeek J, van der Born D, et al. Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. J Med Chem 2011;54:3480–91
   PubMed Web of Science ®Google Scholar
• Alonso D, Vázquez-Villa H, Gamo AM, et al. Development of fluorescent ligands for the human 5-HT1A receptor. ACS Med Chem Lett 2010;1:249–53
   PubMed Web of Science ®Google Scholar
• Medina RA, Sallander J, Benhamu B, et al. Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem 2009;52:2384–92
   PubMed Web of Science ®Google Scholar
• Siracusa MA, Salerno L, Modica MN, et al. Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands. J Med Chem 2008;51:4529–38
   PubMed Web of Science ®Google Scholar
• Paluchowska MH, Bugno R, Tatarczyńska E, et al. The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines. Bioorg Med Chem 2007;15:7116–25
   PubMed Web of Science ®Google Scholar
• Lepailleur A, Bureau R, Paillet-Loilier M, et al. Molecular modeling studies focused on 5-HT7 versus 5-HT1A selectivity. Discovery of novel phenylpyrrole derivatives with high affinity for 5-HT7 receptors. J Chem Inf Model 2005;45:1075–81
   PubMed Web of Science ®Google Scholar
• Vermeulen ES, van Smeden M, Schmidt AW, et al. Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides. J Med Chem 2004;47:5451–66
   PubMed Web of Science ®Google Scholar
• Perrone R, Berardi F, Colabufo NA, et al. Synthesis and structure-affinity relationships of 1-[omega-(4-aryl-1-piperazinyl)alkyl]-1-aryl ketones as 5-HT(7) receptor ligands. J Med Chem 2003;46:646–9
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353–9
   PubMed Web of Science ®Google Scholar
• Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137–51
   PubMed Web of Science ®Google Scholar
• Maxwell CR, Kanes SJ, Abel T, Siegel SJ. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 2004;129:101–7
   PubMed Web of Science ®Google Scholar
• Kanes SJ, Tokarczyk J, Siegel SJ, et al. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007;144:239–46
   PubMed Web of Science ®Google Scholar
• Zagórska A, Pawłowski M, Siwek A, et al. Synthesis and pharmacological evaluation of novel tricyclic[2,1-f]theophylline derivatives. Arch Pharm (Weinheim) 2013;346:832–9
   PubMed Web of Science ®Google Scholar
• Partyka A, Jarosz J, Wasik A, et al. Novel tricyclic[2,1-f]theophylline derivatives of LCAP with activity in mouse models of affective disorders. J Pharm Pharmacol 2014;66:1755–62
   PubMed Web of Science ®Google Scholar
• Zagórska A, Jurczyk S, Pawłowski M, et al. Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives. Eur J Med Chem 2009;44:4288–96
   PubMed Web of Science ®Google Scholar
• Zagórska A, Kołaczkowski M, Bucki A, et al. Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic activity. Eur J Med Chem 2015;97:142–54
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff W. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099–108
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Marcinkowska M, Bucki A, et al. Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem 2014;57:4543–57
   PubMed Web of Science ®Google Scholar
• Bajda M, Guła A, Więckowski K, Malawska B. Determination of lipophilicity of γ-butyrolactone derivatives with anticonvulsant and analgetic activity using micellar electrokinetic chromatography. Electrophoresis 2013;34:3079–85
   PubMed Web of Science ®Google Scholar
• Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov 2010;5:235–48
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Bertin A, Blavet N, et al. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979;57:201–10
   PubMed Web of Science ®Google Scholar
• Aron C, Simon P, Larousse C, Boissier JR. Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 1971;10:459–69
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Bucki A, Feder M, Pawłowski M. Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening. J Chem Inf Model 2013;53:638–48
   PubMed Web of Science ®Google Scholar
• Kowalski P, Jaśkowska J, Bojarski AJ, et al. Evaluation of 1-arylpiperazine derivative of hydroxybenzamides as 5-HT1A and 5-HT7 serotonin receptor ligands: an experimental and molecular modeling approach. J Heterocycl Chem 2011;48:192–8
   Web of Science ®Google Scholar
• Chłoń-Rzepa G, Bucki A, Kołaczkowski M, et al. Arylpiperazinylalkyl aerivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. J Enzyme Inhib Med Chem 2015;25:1–15
   Web of Science ®Google Scholar
• Kurowski MA, Bujnicki JM. Genesilico protein structure prediction meta-server. Nucleic Acids Res 2003;31:3305–7
   PubMed Web of Science ®Google Scholar
• Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381–5
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534–53
   PubMed Web of Science ®Google Scholar
• Gabriel S. Ueber eine Darstellungsweise primärer amine aus den entsprechenden Halogenverbindungen. Chem Ber 1887;20:2224–36
   Google Scholar
• Volk B, Barkoczy J, Hegedus E, et al. Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists. J Med Chem 2008;51:2522–32
   PubMed Web of Science ®Google Scholar
• Leopoldo M, Lacivita E, Contino M, et al. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem 2007;50:4214–21
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Hong Y, et al. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomol Screen 2003;8:453–62
   PubMed Web of Science ®Google Scholar
• Huang J, Si L, Fan Z, et al. In vitro metabolic stability and metabolite profiling of TJ0711 hydrochloride, a newly developed vasodilatory β-blocker, using a liquid chromatography-tandem mass spectrometry method. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3386–92
   PubMed Web of Science ®Google Scholar
• Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl.) 2011;213:265–87
   PubMed Web of Science ®Google Scholar
• Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J Med Chem 2006;49:7559–83
   PubMed Web of Science ®Google Scholar
• Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006;51:578–86
   PubMed Web of Science ®Google Scholar